Is BillionToOne covered by insurance?
Yes, clinical tests offered by BillionToOne—such as its UNITY prenatal screen and Northstar oncology liquid biopsy panels—are widely covered by Medicare, Medicaid, and major private commercial health insurance providers. The company maintains dedicated billing and insurance navigation teams designed to work directly with insurance carriers and healthcare providers to verify coverage, secure prior authorizations, and minimize out-of-pocket expenses for patients. Furthermore, BillionToOne often implements patient financial assistance programs or transparent pricing policies to ensure that individuals facing high deductible plans or out-of-network insurer policies can access necessary genetic testing without unexpected financial burdens.
Related FAQs
American Express Membership Rewards points possess a flexible valuation that varies significantly depending on how you choose to redeem them, meaning their cash value is not a fixed amount.
Bitdeer Technologies Group commands a corporate market capitalization of approximately $2.81 billion USD.
Yes, BillionToOne operates as a publicly traded enterprise. The molecular diagnostics and precision medicine company successfully completed its initial public offering on the NASDAQ Global Select Market, trading under the ticker symbol BLLN.
BillionToOne is widely regarded as an innovative, fast-growing molecular diagnostics and precision health company specializing in advanced prenatal screening and oncology liquid biopsy testing.
BillionToOne has evolved past its early-stage startup origins into a publicly traded commercial-stage molecular diagnostics enterprise.
Yes, BillionToOne, Inc. is a publicly traded enterprise.